Research Paper Volume 13, Issue 7 pp 9522—9541

EGB761 ameliorates chronic cerebral hypoperfusion-induced cognitive dysfunction and synaptic plasticity impairment

EGB761 could relieve the inhibition of neural activity and the structural degeneration of neurons after CCH. The brain sections were developed by Arc (A) and MAP2 (C) antibody to evaluate the neural activity and the structural degeneration. The Arc and MAP2 particles were observed and analyzed in subregions of hippocampus (B, D) (n=3 for 4 group). The hippocampus homogenate was relatively quantitatively assayed by Western blotting with Arc and MAP2 antibody (E, F, G). (Con: n=4; 2VO: n=5; 2VO+EGB761: n=6; EGB761: n=5).

Figure 4. EGB761 could relieve the inhibition of neural activity and the structural degeneration of neurons after CCH. The brain sections were developed by Arc (A) and MAP2 (C) antibody to evaluate the neural activity and the structural degeneration. The Arc and MAP2 particles were observed and analyzed in subregions of hippocampus (B, D) (n=3 for 4 group). The hippocampus homogenate was relatively quantitatively assayed by Western blotting with Arc and MAP2 antibody (E, F, G). (Con: n=4; 2VO: n=5; 2VO+EGB761: n=6; EGB761: n=5).